# Bissan Al-Lazikani

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8792663/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 58<br>papers | 10,964<br>citations | 236925<br>25<br>h-index | 223800<br>46<br>g-index |
| 62<br>all docs | 62<br>docs citations | 62<br>times ranked | 18203<br>citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | How many drug targets are there?. Nature Reviews Drug Discovery, 2006, 5, 993-996. | 46.4 | 3,073 |
| 2 | ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Research, 2012, 40, D1100-D1107. | 14.5 | 3,028 |
| 3 | A comprehensive map of molecular drug targets. Nature Reviews Drug Discovery, 2017, 16, 19-34. | 46.4 | 1,608 |
| 4 | Combinatorial drug therapy for cancer in the post-genomic era. Nature Biotechnology, 2012, 30, 679-692. | 17.5 | 883 |
| 5 | Therapeutic opportunities within the DNA damage response. Nature Reviews Cancer, 2015, 15, 166-180. | 28.4 | 442 |
| 6 | Genomic-scale prioritization of drug targets: the TDR Targets database. Nature Reviews Drug Discovery, 2008, 7, 900-907. | 46.4 | 282 |
| 7 | Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nature Genetics, 2018, 50, 682-692. | 21.4 | 182 |
| 8 | canSAR: an updated cancer research and drug discovery knowledgebase. Nucleic Acids Research, 2016, 44, D938-D943. | 14.5 | 114 |
| 9 | Objective assessment of cancer genes for drug discovery. Nature Reviews Drug Discovery, 2013, 12, 35-50. | 46.4 | 111 |
| 10 | Drug discovery in advanced prostate cancer: translating biology into therapy. Nature Reviews Drug Discovery, 2016, 15, 699-718. | 46.4 | 111 |
| 11 | PDBe-KB: a community-driven resource for structural and functional annotations. Nucleic Acids Research, 2020, 48, D344-D353. | 14.5 | 87 |
| 12 | Minimum information about a bioactive entity (MIABE). Nature Reviews Drug Discovery, 2011, 10, 661-669. | 46.4 | 80 |
| 13 | canSAR: update to the cancer translational research and drug discovery knowledgebase. Nucleic Acids Research, 2019, 47, D917-D922. | 14.5 | 75 |
| 14 | Objective, Quantitative, Data-Driven Assessment of Chemical Probes. Cell Chemical Biology, 2018, 25, 194-205.e5. | 5.2 | 71 |
| 15 | canSAR: updated cancer research and drug discovery knowledgebase. Nucleic Acids Research, 2014, 42, D1040-D1047. | 14.5 | 69 |
| 16 | The kinase polypharmacology landscape of clinical PARP inhibitors. Scientific Reports, 2020, 10, 2585. | 3.3 | 68 |
| 17 | Polypharmacology in Precision Oncology: Current Applications and Future Prospects. Current Pharmaceutical Design, 2017, 22, 6935-6945. | 1.9 | 65 |
| 18 | canSAR: update to the cancer translational research and drug discovery knowledgebase. Nucleic Acids Research, 2021, 49, D1074-D1082. | 14.5 | 63 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | canSAR: an integrated cancer public translational research and drug discovery resource. Nucleic Acids Research, 2012, 40, D947-D956. | 14.5 | 62 |
| 20 | Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology. Current Opinion in Pharmacology, 2013, 13, 486-496. | 3.5 | 55 |
| 21 | Drugging cancer genomes. Nature Reviews Drug Discovery, 2013, 12, 889-890. | 46.4 | 47 |
| 22 | PDBe-KB: collaboratively defining the biological context of structural data. Nucleic Acids Research, 2022, 50, D534-D542. | 14.5 | 46 |
| 23 | Distinctive Behaviors of Druggable Proteins in Cellular Networks. PLoS Computational Biology, 2015, 11, e1004597. | 3.2 | 43 |
| 24 | Target 2035 â€“ update on the quest for a probe for every protein. RSC Medicinal Chemistry, 2022, 13, 13-21. | 3.9 | 39 |
| 25 | Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer. ELife, 2017, 6, . | 6.0 | 32 |
| 26 | Public resources for chemical probes: the journey so far and the road ahead. Future Medicinal Chemistry, 2021, 13, 731-747. | 2.3 | 24 |
| 27 | Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases. Oncogene, 2019, 38, 5905-5920. | 5.9 | 23 |
| 28 | JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer. Cancer Research, 2022, 81, 1087-1100. | 0.9 | 23 |
| 29 | Transforming cancer drug discovery with Big Data and AI. Expert Opinion on Drug Discovery, 2019, 14, 1089-1095. | 5.0 | 22 |
| 30 | Personalized Medicine: Patient-Predictive Panel Power. Cancer Cell, 2012, 21, 455-458. | 16.8 | 16 |
| 31 | Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers. Molecular Cancer Therapeutics, 2019, 18, 1396-1404. | 4.1 | 14 |
| 32 | Evolution of kinase polypharmacology across HSP90 drug discovery. Cell Chemical Biology, 2021, 28, 1433-1445.e3. | 5.2 | 13 |
| 33 | A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma. European Journal of Cancer, 2013, 49, 2512-2521. | 2.8 | 11 |
| 34 | Rational design of non-resistant targeted cancer therapies. Scientific Reports, 2017, 7, 46632. | 3.3 | 11 |
| 35 | Blocking the survival of the nastiest by HSP90 inhibition. Oncotarget, 2016, 7, 3658-3661. | 1.8 | 11 |
| 36 | Unpicking the Combination Lock for Mutant BRAF and RAS Melanomas. Cancer Discovery, 2013, 3, 14-19. | 9.4 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Solution structure of the Hop TPR2A domain and investigation of target druggability by NMR, biochemical and in silico approaches. Scientific Reports, 2020, 10, 16000. | 3.3 | 8 |
| 38 | SiGNet: A signaling network data simulator to enable signaling network inference. PLoS ONE, 2017, 12, e0177701. | 2.5 | 7 |
| 39 | The Molecular Basis of Predicting Druggability. , 0, , 1315-1334. | | 5 |
| 40 | Tuning Local Hydration Enables a Deeper Understanding of Proteinâ€“Ligand Binding: The PP1-Src Kinase Case. Journal of Physical Chemistry Letters, 2021, 12, 49-58. | 4.6 | 5 |
| 41 | canSAR chemistry registration and standardization pipeline. Journal of Cheminformatics, 2022, 14, . | 6.1 | 5 |
| 42 | Minimizing bias in target selection by exploiting multidisciplinary Big Data and the protein interactome. Future Medicinal Chemistry, 2016, 8, 1711-1716. | 2.3 | 4 |
| 43 | Leveraging Human Genetics to Guide Cancer Drug Development. JCO Clinical Cancer Informatics, 2018, 2, 1-11. | 2.1 | 3 |
| 44 | Unravelling the context specificity of signalling in KRAS mutant cancers: Implications for design of clinical trials. Annals of Oncology, 2018, 29, iii7. | 1.2 | 3 |
| 45 | Genomics, bio specimens, and other biological data: Current status and future directions. Medical Physics, 2018, 45, e829-e833. | 3.0 | 3 |
| 46 | Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligenceâ€“Enabled Studies of Acute Phosphoproteomic Changes. Molecular Cancer Therapeutics, 2022, 21, 1020-1029. | 4.1 | 3 |
| 47 | Abstract 2730: RNAi knockdown or chemical inhibition of anaphase-promoting complex components is synthetic lethal with HSP90 inhibition. , 2014, , . | | 1 |
| 48 | Abstract B096: canSAR, a cancer research and drug discovery knowledgebase. Molecular Cancer Therapeutics, 2018, 17, B096-B096. | 4.1 | 1 |
| 49 | Shouldn't enantiomeric purity be included in the 'minimum information about a bioactive entity? Response from the MIABE group. Nature Reviews Drug Discovery, 2012, 11, 730-730. | 46.4 | 0 |
| 50 | Abstract 4164: The druggable proteome: Identifying novel target families for cancer. , 2014, , . | | 0 |
| 51 | Abstract 4383: SOCRATES: integrating ex vivo and in silico analysis to identify optimal drug combinations for patients. , 2016, , . | | 0 |
| 52 | Abstract 3099:KRASand clinical context: Differential dynamic signaling output ofKRASmutant lung, colorectal and pancreatic cancer cell lines when exposed to targeted anticancer drugs. , 2016, , . | | 0 |
| 53 | Abstract 996: A translational phosphoproteomic approach to study differences inKRASsignaling in pancreatic, colorectal and lung cancers. , 2017, , . | | 0 |
| 54 | Abstract A024: Probe Miner: objective, quantitative, data-driven assessment of chemical probes for target validation. , 2018, , . | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Abstract 776: Utilising genetic susceptibility and big data to inform novel cancer therapies. , 2018, , . | | 0 |
| 56 | Abstract 1821: Genome-wide genetic screens define the drug resistance landscape of BRAF mutant colon cancer. , 2018, , . | | 0 |
| 57 | Abstract A067: Targeting the bromodomain and extra-terminal (BET) family proteins and beyond in metastatic castration-resistant prostate cancer (mCRPC): Overcoming aberrant androgen receptor (AR) signaling. , 2018, , . | | 0 |
| 58 | Abstract LB-C01: The kinase polypharmacology landscape of clinical PARP inhibitors. , 2019, , . | | 0 |